1
|
Ahmadi Ghezeldasht S, Momen Heravi M, Valizadeh N, Rafatpanah H, Shamsian SA, Mosavat A, Rezaee SA. Development of a Novel HTLV-1 Protease: Human Fcγ1 Recombinant Fusion Molecule in the CHO Eukaryotic Expression System. Appl Biochem Biotechnol 2023; 195:1862-1876. [PMID: 36399306 PMCID: PMC9673214 DOI: 10.1007/s12010-022-04259-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/08/2022] [Indexed: 11/19/2022]
Abstract
Human T-cell leukaemia virus type 1 (HTLV-1) is the causative agent of two life-threatening diseases, adult T cell leukaemia/lymphoma (ATLL), and HTLV-1-associated myelopathy/tropical spastic (HAM/TSP). HTLV-1 protease (HTLV-1-PR) is an aspartic protease that represents a promising target for therapeutic purposes like human immunodeficiency virus-PR inhibitors (HIV-PR). Therefore, in this study, the human Fc fusion recombinant-PR (HTLV-1-PR:hFcγ1) was designed and expressed for two applications, finding a blocking substrate as a potential therapeutic or a potential subunit peptide vaccine. The PCR amplified DNA sequences encoding the HTLV-1-PR from the MT2-cell line using specific primers with restriction enzyme sites of Not1 and Xba1. The construct was then cloned to pTZ57R/T TA plasmid and, after confirming the PR sequence, subcloned into the pDR2ΔEF1α Fc-expression vector to create pDR2ΔEF1α.HTLV-1-PR:hFcγ1. The integrity of recombinant DNA was confirmed by sequencing to ensure that the engineered construct was in the frame. The recombinant fusion protein was then produced in the Chinese hamster ovary cell (CHO) system and was purified from its supernatant using HiTrap-rPA column affinity chromatography. Then, the immunofluorescence assay (IFA) co-localisation method showed that HTLV-1-PR:hFc recombinant fusion protein has appropriate folding as it binds to the anti-Fcγ antibody; the Fcγ1 tag participates to have HTLV-1-PR:hFcγ1 as a dimeric secretory protein. The development and production of HTLV-1-PR can be used to find a blocking substrate as a potential therapeutic molecule and apply it in an animal model to assess its immunogenicity and potential protection against HTLV-1 infection.
Collapse
Affiliation(s)
- Sanaz Ahmadi Ghezeldasht
- Inflammation and Inflammatory Diseases Division, Medical Campus, Immunology Research Center, Mashhad University of Medical Sciences, Azadi Square, Mashhad, 9177948564 Iran
- Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR), Azadi Square, Ferdowsi University Campus, Razavi Khorasan, Mashhad, 9177949367 Iran
| | - Mastoureh Momen Heravi
- Inflammation and Inflammatory Diseases Division, Medical Campus, Immunology Research Center, Mashhad University of Medical Sciences, Azadi Square, Mashhad, 9177948564 Iran
| | - Narges Valizadeh
- Inflammation and Inflammatory Diseases Division, Medical Campus, Immunology Research Center, Mashhad University of Medical Sciences, Azadi Square, Mashhad, 9177948564 Iran
| | - Houshang Rafatpanah
- Inflammation and Inflammatory Diseases Division, Medical Campus, Immunology Research Center, Mashhad University of Medical Sciences, Azadi Square, Mashhad, 9177948564 Iran
| | - Seyed Aliakbar Shamsian
- Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR), Azadi Square, Ferdowsi University Campus, Razavi Khorasan, Mashhad, 9177949367 Iran
- Department of Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Arman Mosavat
- Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR), Azadi Square, Ferdowsi University Campus, Razavi Khorasan, Mashhad, 9177949367 Iran
| | - Seyed Abdolrahim Rezaee
- Inflammation and Inflammatory Diseases Division, Medical Campus, Immunology Research Center, Mashhad University of Medical Sciences, Azadi Square, Mashhad, 9177948564 Iran
| |
Collapse
|